Freedom Meditech Presents Data Showing Benefits Of Non-Invasive Diabetes Screening And Glucose Monitoring In The Eye At London Conference
People with diabetes or who are at risk of developing the disease - now estimated at over 400 million globally - could reduce complications, improve quality of life and reduce healthcare costs by using new non-invasive technology to screen for and monitor the illness, according to a presentation by Freedom Meditech at the 6th Annual Diabetes and Diabetic Retinopathy Conference in London, England. "We believe that our proprietary technologies, which non-invasively measure changes in the eye to detect and monitor diabetes, could identify the presence of the disease earlier, and once found, reduce the pain and inconvenience barriers currently required to maintain optimal glycemic control, " said Craig Misrach, President & CEO of Freedom Meditech. "Early disease detection and maintaining tight glucose control are two important keys to reducing the proliferation and associated costs of diabetes complications such as diabetic retinopathy, macular degeneration, and blindness." According to the American Diabetes Association, diabetes complications directly attribute to over $120 billion in excess medical expenditures in the United States annually.
Osiris Therapeutics, Inc. (NASDAQ:OSIR) today announced that it has achieved a $750, 000 milestone payment from the Juvenile Diabetes Research Foundation (JDRF) for completing enrollment in a Phase II clinical trial evaluating Prochymal, an adult mesenchymal stem cell (MSC) therapy, as a treatment for patients recently diagnosed with type 1 diabetes. The milestone is the fourth in a series of payments resulting from JDRF's partnership with Osiris for the development of a therapy for type 1 diabetes. In total, 63 patients were treated at 20 leading centers in this double-blind, placebo controlled trial. The study is evaluating the safety and efficacy of Prochymal in preserving insulin production in patients newly diagnosed with type 1 diabetes. The trial initially included patients 18 to 30 years of age. In July 2009, after reviewing safety data, the U.S. Food and Drug Administration (FDA) allowed Osiris to expand the trial to include pediatric patients. "Completing the enrollment phase of this landmark trial represents a significant milestone for the development of stem cell therapies for type 1 diabetes, " said C.
Increase In Mortality Risk When Intensive Glucose Control For Diabetes Lowers Blood Glucose Too Far Hypoglycaemia
An article Online First and in an upcoming edition of The Lancet reports that new research indicates that intensive treatment to control blood glucose can lower it too far and cause hypoglycaemia. This can increase mortality. Uncontrolled high blood glucose (hyperglycaemia) in patients with diabetes is known to also increase mortality. Therefore in order to lower the risk to patients, blood glucose level targets should have lower as well as upper limits. In addition, it is reported that patients with type 2 diabetes given insulin-based regimens have a 50 percent increased mortality risk compared to those given combination oral therapy. The article is the work of Dr Craig Currie, School of Medicine, Cardiff University, UK, and colleagues. When controlling blood sugar, the objective is to maintain glycated haemoglobin (HbA1c) to a normal range. Glycated haemoglobin is a form of haemoglobin used to identify the average plasma glucose concentration over prolonged periods of time. The HbA1c level is proportional to average blood glucose concentration over the previous four weeks to three months.
Calibra Receives 510 k Clearance For The Finesse trade; Insulin Patch-Pen, A Novel Way To Deliver Insulin
Calibra Medical announced today that the U.S. Food and Drug Administration (FDA) has cleared Finesse, the company's insulin patch-pen. Finesse represents a new category of simple mechanical devices intended to make insulin therapy adherence easier for patients to achieve at an affordable price point. 93% of type 1 and type 2 diabetes patients on insulin in the U.S. and E.U., estimated at over 10 million patients, use syringes and pens and are challenged to overcome the difficulty, and often the social stigma, associated with delivering bolus, or mealtime, insulin. Calibra's Finesse is the first of several non-electronic devices under development by the company that simplify mealtime insulin delivery. About Finesse: A New Way to Deliver Insulin Accurately, Affordably and Discretely Measuring roughly 2" long, 1" wide and Â " thick, Finesse is a small plastic device designed to adhere comfortably to a patient's skin. Finesse is able to hold and deliver prescribed amounts of insulin over multiple days while remaining firmly in place throughout a patient's daily activities, including showering, exercising and sleeping.
Novo Nordisk (NVO) announced that the U.S. Food and Drug Administration (FDA) approved the new drug application for Victoza® (liraglutide [rDNA origin] injection), the first once-daily human glucagon-like peptide-1 (GLP-1) analog for the treatment of type 2 diabetes. Victoza is indicated as an adjunct to diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus. Victoza was evaluated in The Liraglutide Effect and Action in Diabetes (LEAD) phase III trials, the most comprehensive clinical development program conducted to date by Novo Nordisk in type 2 diabetes. In clinical studies including use as monotherapy and in combination with standard diabetes treatments, Victoza produced significant reductions in A1C and also was associated with weight loss. "Novo Nordisk is committed to developing safe and effective drugs to treat diabetes, which is why the FDA approval of Victoza represents such an important milestone for the company and for people with type 2 diabetes, " says Alan C.
Intensive Insulin Therapy For Patients Treated For Septic Shock With Hydrocortisone Does Not Show Survival Benefit
Treating adults with septic shock with intensive insulin therapy to counter elevated blood glucose levels associated with corticosteroid therapy did not result in a reduced risk of in-hospital death, compared to patients who received conventional insulin therapy, according to a study in the January 27 issue of JAMA. The researchers also found that adding a 2nd corticosteroid to treatment did not significantly reduce the risk of death within the hospital. Septic shock is a major complication of infectious diseases, with a mortality rate of 60 percent within a short period, according to background information in the article. Corticosteroids are used in the treatment of septic shock and may provide a survival benefit, but their use is associated with hyperglycemia. Djillali Annane, M.D., of the HÃ pital Raymond PoincarÃ, Garches, France, and colleagues with the Corticosteroids and Intensive Insulin Therapy for Septic Shock (COIITSS) trial examined whether normalization of blood glucose levels with intensive insulin treatment would improve outcomes for adults with septic shock treated with hydrocortisone.
Poorer Diabetics And Those From Ethnic Minorities Receive Worse Care Than Other Patients In Countries With Universal Health Coverage
People with lower socioeconomic status and those belonging to ethnic minority groups receive worse health care in the treatment of diabetes than the rest of patients in the world's most developed countries. This conclusion emerges from a research conducted at the University of Granada which has accomplished the most comprehensive bibliographic review worldwide to date on health care of this disease in the Organization for Economic Co-operation and Development (OECD) countries that have universal coverage health systems. The OECD brings together the most advanced and developed countries on the planet, and its members account for 70% of the global market. This work has been carried out by Ignacio Ricci Cabello, from the Department of Nutrition and Food Science at the University of Granada, and directed by professors Isabel Ruiz PÃ rez (Andalusian School of Public Health) and Soledad MÃ rquez CalderÃ n (Andalusian Regional Ministry of Health). Its main objective was to determine whether health systems provide equitable healthcare to all diabetics, regardless of gender, race, socioeconomic status or country of origin or they do not.
In people who put on a lot of weight, or whose bodies start developing the inability to use insulin effectively that leads toward type 2 diabetes, the pancreas typically ramps up its supply of insulin-generating "beta" cells, at least partly by replication of the existing cells. Researchers at Joslin Diabetes Center and their colleagues now have identified a cell-cycle protein that is essential for beta-cell replication to respond successfully to insulin resistance. The finding may point toward eventual therapies for preventing or treating type 2 diabetes. In a paper published in Diabetes on January 26, biologists in the labs of Joslin Principal Investigator Rohit N. Kulkarni, M.D., Ph.D., and Anil Bhushan, Ph.D., at the University of California at Los Angeles used a genetic approach to show that a protein called cyclin D2 is needed for this beta-cell response in mice. Cyclin D2 is a member of a small family of proteins that aid in the cell cycle, by which cells divide into two.
The U.S. Food and Drug Administration today approved Victoza (liraglutide), a once-daily injection to treat type 2 diabetes in some adults. Victoza is intended to help lower blood sugar levels along with diet, exercise, and selected other diabetes medicines. It is not recommended as initial therapy in patients who have not achieved adequate diabetes control on diet and exercise alone. Insulin is a hormone that helps prevent sugar (glucose) from building up in the blood. People with type 2 diabetes have difficulty making and using insulin. Victoza is in a class of medicines known as glucagon-like peptide-1 (GLP-1) receptor agonists that help the pancreas make more insulin after eating a meal. "Diabetes is a leading cause of death and disability, with more than 1.5 million new cases diagnosed annually, " said Mary Parks, M.D., director, Division of Metabolism and Endocrinology Products in the FDA's Center for Drug Evaluation and Research. "Controlling blood sugar levels is very important to preventing or reducing the long term complications of diabetes, and Victoza offers certain patients with type 2 diabetes a treatment option for controlling their blood glucose levels.
We are looking for more media volunteers to help us raise awareness of diabetes. A media volunteer is someone who is willing to be interviewed by a journalist. When there is a diabetes news story in the papers or on TV or radio, the story often includes an interview with a person with diabetes. The media likes to have a 'human face' to the story, somebody who the audience can relate to. Making research relevant For example, if there is a news story about a research breakthrough, a media volunteer can show what relevance the research may offer to people with diabetes, instead of the story just being about scientific facts and figures. Please get in touch If you are interested, please contact the Media Relations team on 020 7424 1165 or email email@example.com. We are particularly looking for people with diabetes from Black, Asian and ethnic minority backgrounds as these communities are often underrepresented in the media. What to expect Journalists often come to the Media Relations team at Diabetes UK requesting a media volunteer.